Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study

Tafasitamab combined with lenalidomide was approved in Europe in 2021 for transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. Approval was based on the L-MIND study, which demonstrated a 57.5% overall response rate (ORR), 41.3% complete response (CR) rate, 12.1 mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, Olivier Tournilhac, Luc-Matthieu Fornecker, Frédéric Maloisel, Lauris Gastaud, Eric Durot, Adrian Tempescul, Thorsten Braun, Vadim Ivanov, Brieuc Cherel, Caroline Serrier, Jeremy Delage, Abderrazak El Yamani, Baptiste Delapierre, Laure Lebras, Elsa Lestang, Camille Villesuzanne, Philippe Agape, Guillaume Escure, Ludovic Fouillet, Christophe Nicol, Gaëlle Olivier, Anthony Levy, Anne-Sophie Le Bris, Ophélie Cassuto, Laura Jacquemelle, Corinne Haioun, Charles Herbaux
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-05-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/12058
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items